June 1, 2021 -- Samsung Biologics said that it plans to add messenger RNA (mRNA) vaccine drug substance production to its suite of manufacturing capabilities.
The company's current facility in Songdo, South Korea, is expected to be capable of current good manufacturing practice (cGMP) operations for mRNA vaccine drug substance production by the first half of 2022. As a result, Samsung Biologics will be able to provide end-to-end mRNA vaccine manufacturing services, ranging from bulk substances to aseptic fill/finish including labeling and packaging, as well as cold chain storage, according to the vendor.